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Regulatory T cells: immune suppression and beyond
Yisong Y Wan
Foxp3-expressing regulatory T cells (Tregs) were originally identified as critical in maintaining self-tolerance and immune homeostasis.
The immunosuppressive functions of Tregs are widely acknowledged and have been extensively studied. Recent studies have revealed
many diverse roles of Tregs in shaping the immune system and the inflammatory response. This review will discuss our efforts as well as
the efforts of others towards understanding the multifaceted function of Tregs in immune regulation.
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INTRODUCTION
Mammals have evolved complex immune strategies to fight foreign
pathogens and to maintain health. Adaptive and innate immunity are
the two fundamental components of the immune response. Together,
they form a defensive front against pathogens. Innate immunity is
mediated mainly by macrophages and dendritic cells (DCs), which
recognize classes of microorganisms. T and B cells comprise the major
task force carrying out the adaptive immune response, and they have
highly antigen-specific surface receptors. Most T cells recognize specific
antigens and then differentiate into effector T cells to promote immune
responses. By using quasi-random recombination mechanisms, thy-
mus-derived T cells can potentially generate infinite numbers of spe-
cificities that are reactive to foreign and self-antigens. Self-reactive T
cells can cause autoimmune diseases in the host if they are not tightly
controlled. Multiple processes therefore are in place to suppress the
generation or the function of self-reactive T cells. Self-reactive T cells
can be deleted in the thymus as well as in the periphery. Such elim-
ination processes are nevertheless incomplete, resulting in small popu-
lations of mostly low-affinity self-reactive T cells in the periphery that
can potentially initiate an autoimmune response. Fortunately, active
immunosuppressive mechanisms exist to suppress these autoreactive T
cells. Great progress has been made in understanding the cellular and
molecular components of immunosuppression. Active immuno-
suppression is mediated mostly through either cytokines or specialized
cells. The immunosuppressive cells, previously called suppressor cells1
and now usually termed regulatory T cells (Tregs), play critical roles in
suppressing the immune response. For years, much effort has been
devoted to investigating the immunosuppressive functions of Tregs
under normal and immunopathological conditions. Recently, increas-
ing evidence suggests that Tregs might also turn into effector T cells
that may promote immune responses. Thus, while Tregs are mainly
viewed as critical mediators for immunosuppression, they in fact pos-
sess many diverse functions in immune regulation. Here we will review
the evolution of our views on the functions of Tregs.
Tregs AND DOMINANT IMMUNOSUPPRESSION
The concept of immunosuppression was proposed by Gershon et al.1–3
in the early 1970s. The inability to identify the cell types performing
immunosuppression impeded the validation of this concept and hin-
dered development in this research area. It was not until a study
performed by Sakaguchi et al. in 1995 that a subset of T cells with
markedly increased expression of CD25 was discovered, named sup-
pressor T cells, and later referred to as regulatory T cells (Tregs).4 In
recent years, substantial progress has been made in identifying differ-
ent types of Tregs as well as in understanding how these cells are
generated and function. Based on cell surface markers or cytokine
secretion profiles, Tregs can be generally grouped into two categories:
naturally occurring Tregs (nTregs) and induced Tregs (iTregs).
nTregs comprise a subset of CD4 T cells that develop in the thymus
and constitutively express cell surface IL-2 receptor-a chain (CD25).
CD41CD251 nTregs comprise approximately 10–20% of peripheral
CD4 T cells in mice and in humans. nTregs are critical for maintaining
self-tolerance, as disruption of thymic development or peripheral
maintenance of these cells invariably results in the development of
autoimmunity. A cluster of cell surface molecules besides CD25, such
as cytotoxic T lymphocyte antigen-4 (CTLA-4), glucocorticoid-
induced tumor-necrosis factor receptor family-related gene and
lymphocyte activation antigen-3, have also been used to differentiate
nTregs from conventional T cells.5 Transforming growth factor (TGF)-
b is expressed in nTregs at high levels as a cell surface-bound form.6,7
nTregs suppress immune responses in an antigen-independent fashion
in vitro and in vivo.5,8–10 Foxp3, an X-linked transcription factor
belonging to the fork-head family, is specifically and highly expressed
in nTregs.11 Thus, Foxp3 is currently used as the most reliable molecu-
lar marker for nTregs.
Conventional T cells are able to gain immunosuppressive activities
and thus become iTregs. In the presence of exogenous TGF-b, naive
CD4 T cells upregulate Foxp3 expression through de novo mecha-
nisms and become immunosuppressive.12,13 Similar to nTregs,
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Foxp3-expressing iTregs also express higher levels of CD25.12 In addi-
tion, TGF-b and IL-10 expression as well as secretion were found to be
substantially upregulated in iTregs. iTregs not only are able to be
generated in vitro but also can be induced in vivo.14 As a transcription
factor specifically expressed in Tregs, Foxp3 has served as a surrogate
marker for these cells. Therefore, to study the function and regulation
of Tregs, different mouse models have been developed by various
groups to mark the Foxp3-expressing T cells with fluorescent pro-
teins—enhanced green fluorescent proteins (EGFP) or red fluorescent
protein, through genetic manipulations. By purifying CD4 T cells
which express these fluorescent markers, nTregs and iTregs generated
in vivo can be isolated.
For the last decade, the research on Tregs has focused on their
immunosuppressive function. The essential role of Tregs in immuno-
suppression is now indisputable. Yet the mechanisms by which Tregs
carry out their function remain ill defined. Nevertheless, it is generally
agreed that Tregs suppress immune responses through multiple
mechanisms including cell contact-dependent and -independent
mechanisms. Several surface molecules preferentially expressed by
Tregs are proposed to be important for their function. For example,
CD25, a high-affinity IL-2-binding receptor, is highly expressed by the
nTreg. The peripheral maintenance of nTregs appears to be dependent
on IL-2 signaling,15–17 which is also important for the proliferation
and survival of activated effector T cells. It is therefore hypothesized
that one mechanism of nTreg suppression of conventional T-cell
activation is through competition for IL-2 consumption.18–20
However, studies showing that CD25-deficient nTregs possess intact
suppressive activity question the validity of this hypothesis.16 CTLA-4,
another surface molecule preferentially expressed by nTregs,5 is
important for inhibiting immune activation by competing for costi-
mulatory receptor ligands expressed on innate cells21 as well as inhib-
iting the function of antigen-presenting cells.22,23 Thus, it is suggested
that CTLA-4 is important for nTreg-mediated immunosuppression.
However, there is earlier genetic evidence against the critical roles for
CTLA-4 in nTreg function, as the function of nTregs deficient in
CTLA-4 appeared to be normal in vitro and in vivo.24,25 Antibody-
mediated blockage of CTLA-4 was shown to abrogate nTreg function.
It however remains unknown if this was due to a non-specific effect
or a simultaneous blockage of CTLA-4 and its potential homolog(s)
with redundant functions. Nevertheless, a recent study in which CTLA-
4 is specifically deleted in Tregs definitively showed that CTLA-4
expression in Tregs is critical in mediating Treg function. CTLA-4-
deficient Tregs lost suppressive activity and failed to prevent the onset
of autoimmunity and systemic inflammation in vivo.26 Recent studies
revealed unique roles for T helper (Th)-specifying factors in control-
ling Treg function and immune responses. When interferon (IFN)
regulatory factor-4, a Th2-specifying factor, was specifically deleted
in Tregs, enhanced Th2 immunity was observed.27 In addition, when
STAT3, a factor important for Th17 differentiation, was specifically
deleted in Tregs, enhanced Th17 immunity was observed.28 Moreover,
T-bet, a Th1-specifying factor, was found to be upregulated in Tregs
upon IFN-c stimulation. Such upregulation appeared to be important
for the expression of CXCR3 and the survival of Tregs.29 This result
thus suggests that Th-specifying factors are expressed by Tregs under
certain conditions to promote immunosuppression in a manner
specific to ongoing immune responses.
Cytokines also play important roles in nTreg function. TGF-b
appears to be critical in mediating nTreg function, as T cells from
CD4-dnTbRII mice that are unresponsive to TGF-b are refractory
to Treg-mediated suppression in vitro and in vivo.6,30,31 Despite the
fact that TGF-bmRNA is not elevated in nTregs, it is suggested that the
membrane-bound form of TGF-b is increased in nTregs and is
important for their function.6,7 IL-10 is another immunosuppressive
cytokine preferentially expressed in Tregs.32,33 and is important in
mediating the functions of these cells.32,34 Besides suppressing effector
T-cell function directly, Tregs dampen immune responses through
regulating innate components, such as DCs. nTregs can potentially
induce tolerogenic DCs through CTLA-4 engagement-induced tryp-
tophan catabolism.35 In addition, it appears that Tregs destabilize the
interaction between antigenic DCs and conventional T cells to prevent
the activation of T cells.36 It is therefore clear now that multiple
mechanisms are involved in Treg-mediated immunosuppression.
Much work is needed in the future to identify cell contact-dependent
and -independent mechanisms critical for controlling Treg function.
DIVERSE FUNCTIONS OF Tregs BEYOND
IMMUNOSUPPRESSION
While we are still at the tip of the iceberg of understanding how Tregs
control immunosuppression, emerging evidence suggests that Tregs
are not only immunosuppressive but also able to become other types
of effector Th cells to promote but not to suppress immune responses.
To comprehend this idea, we will have to first clarify the definition of
Tregs. Tregs have been traditionally defined by immunosuppressive
activity since their discovery. However, because Foxp3 expression is
accepted as a surrogate marker for identifying Treg lineage, Tregs have
been redefined as Foxp3-expressing cells. Thus, Foxp3-expressing cells
are now dubbed Treg lineage cells instead of functional immunosup-
pressing cells. By accepting this new definition, we start to realize that
cells of Treg lineage, or Foxp3-expressing cells, play much more
diverse roles than suppression in controlling immune responses.
Before we explore the conversion of Tregs into other types of Th cells,
we shall review what other types of Th cells have been identified and
their characteristics, function and generation.
Th1 cells produce cytokine IFN-c, TNF-a and TNF-b to stimulate
innate and T-cell immune responses. The prominent function for Th1
cells is to promote cell-mediated immunity characterized by cellular
cytolytic activity. Th1 cells are important to protect the host from
obligate intracellular pathogens, such as the protozoal parasite
Leishmania major,37–39 the bacteria Mycobacterium avium40 and
Salmonnella typhimurium41 as well as viruses herpes simplex virus,42
influenza A virus43 and vaccinia virus.44 Aberrant proinflammatory
properties of Th1 cells can cause tissue damage and elicit unwanted
inflammatory disease as well as self-reactivity including inflammatory
bowel disease,45,46 graft-versus-host disease47 and autoimmune dis-
orders, such as insulin-dependent diabetes mellitus48,49 and rheum-
atoid arthritis.50 IL-12 produced by activated innate immunity is a
potent inducer for Th1 differentiation.51–54 Th1 differentiation and
function are controlled through Th1-specific transcription factors. T-
bet, also known as Tbx21,55 belongs to the T-box family of transcrip-
tion factors and is the only known T-box gene specifically expressed in
the lymphoid system. T-bet is rapidly and specifically induced in
developing Th1 cells and is critically involved in initiating Th1
development, and thus, T-bet is recognized as a master regulator for
Th1 differentiation. STAT4 is a transcription factor critical for IL-12
signaling and thus the full commitment of Th1 cells.56–58
Th2 cells are defined as producers of IL-4, IL-5, IL-9, IL-10 and IL-
13. The Th2 response is often associated with humoral responses and is
important to resist extracellular pathogens, such as helminths and
nematodes.59,60 Th2 cells are also important for mucosal immunity
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inflammatory airway diseases, such as atopic asthma and allergy.61–67
IL-4 is the most prominent, if not the only, cytokine known to have the
greatest influence in directing Th2 differentiation.68,69 The presence of
IL-4, even if endogenously derived, is essential for Th2 differenti-
ation.70–73 GATA3, a member of the GATA family of transcription
factors, is sufficient and required for Th2 differentiation.74–76
Therefore, GATA3 is regarded as the master regulator for Th2 differ-
entiation. STAT6 activated by IL-4 stimulation is the major signal
transducer in IL-4-mediated Th2 differentiation.77,78 One of the
mechanisms by which STAT6 promotes Th2 differentiation is through
inducing high levels of transcription factor GATA3.79,80
Th17 cells are a newly identified class of effector T cell, which pro-
duces IL-17A and IL-17F. Th17 cells have been suggested to contribute
to resistance to Listeria, Salmonella, Toxoplasma, Cryptococcus,
Leishmania and Francisella.81–83 In addition to controlling infection,
Th17 cells play a critical role in the induction and propagation of
autoimmunity. IL-17 expression has been associated with auto-
immune diseases such as multiple sclerosis, rheumatoid arthritis,
psoriasis and inflammatory bowel disease as well as allergic res-
ponses.84,85 TGF-b and IL-6 act cooperatively and non-redundantly
to promote Th17 commitment.86–88 IL-21, an IL-2 family member
recently found to be highly produced by Th17 cells, can substitute
for IL-6 to induce Th17 cells along with TGF-b.89–91 Retinoic acid-
related orphan receptors (RORs) are the key transcription factors in
Th17 differentiation. ROR-a and ROR-ct are both critical and some-
what redundant in promoting Th17 differentiation.92,93
Follicular helper T (Tfh) cells express high levels of CXCR5. B cell-
promoting cytokines IL-10 and IL-21 are highly produced by Tfh cells,
which are not typically associated with other types of Th cells.94–97 IL-
21 has been found to be critical for Tfh differentiation.95,97 Bcl-6 was
recently reported to be a transcription factor that can be upregulated
by IL-21 signaling and is critical for Tfh generation.98
Plasticity of Tregs in vitro
Treg to Th17 conversion. Under culture conditions, Treg to Th17 con-
version has been extensively studied. The earlier observation that IL-6
was able to abrogate Treg-suppressive activity99 was intriguing. The
activation of innate cells, such as DCs, was able to abrogate the sup-
pressive function of Tregs. This effect was largely due to the secretion
of proinflammatory cytokine IL-6 by DCs because addition of exo-
genous IL-6 alone could abrogate Treg suppression. In addition, IL-6
production by the DCs is required for abolishing Treg suppressive
activity, as IL-6 deficient DCs or antibody neutralization of IL-6 in
the DC/T cell coculture restored Treg suppression. In the ensuing
years, IL-6 was found to be important to suppress Treg generation
and to promote Th17 differentiation. TGF-b promotes the generation
of Foxp3-expressing Tregs. However, IL-6 antagonizes TGF-b-
induced Treg generation and promotes Th17 differentiation.86,87
These reports further confirmed the notion that naive T cells can be
directed into different types of effector T cells under different cytokine
milieux. It nevertheless raises the possibility that Tregs may be able to
convert into Th17 upon IL-6 stimulation due to the fact that TGF-b is
highly expressed by Tregs. Indeed, freshly isolated nTregs produced a
large amount of TGF-b upon stimulation in vitro. In the presence of
IL-6, Foxp3-expressing cells expressed IL-17, suggesting that nTregs
can be converted into Th17-like cells after commitment to the Treg
program.100,101 Not only are nTregs able to be converted into Th17
cells, but also TGF-b-induced iTregs have been shown to turn into
IL17-producing cells upon IL-6 stimulation.101 In these reports, Treg
to Th17 conversion was concomitant with downregulation of Foxp3,
whose expression has been shown to suppress ROR-ct expression and
to shut down the Th17 program.100,102 Therefore, the downregulation
of Foxp3 seems to be important to license Treg to Th17 differentiation.
IL-6-dependent signaling is sufficient in both suppressing Foxp3
expression and promoting IL-17 expression. It is specifically required
for the downregulation of Foxp3, as STAT3-deficient mice failed to
repress Foxp3 following IL-6 stimulation. Thus, IL-6 signaling appears
to the molecular switch between Tregs and Th17. Note that, although
IL-17 expression in Tregs coincides with Foxp3 downregulation, the
total abolishment of Foxp3 is not required for Th17 conversion
of Tregs because cells expressing both Foxp3 and IL-17 were
found.100, 101 Thus, Foxp3 expression and IL-17 expression are not
mutually exclusive.
Treg conversion to other Th cells. Unlike Treg to Th17 conversion, few
studies have addressed the potential of Foxp3-expressing cells to pro-
duce IFN-c, and thus to undergo Th1 conversion in vitro, with some-
what controversial findings. In one study, Tregs were not found to be
able to produce IFN-c, even under Th1-polarizing conditions.101
However, in the other study, Foxp3-expressing cells were found to
produce IFN-c under Th1 conditions in Foxp3-expressing and
Foxp3-non-expressing populations103,104 (our unpublished obser-
vation). Such discrepancy in the results could be due to different
experimental conditions. Without addition of a large amount of exo-
genous IL-2, Foxp3-expressing cells display an anergic phenotype and
can not be activated. This might account for the lack of cytokine
production observed in the first report. However, when a high dose
of exogenous IL-2 is provided in the culture to force Tregs to exit the
anergic state, as described in the second report, Tregs generate sub-
stantial amounts of IFN-c to become Th1 cells103,104 (our unpublished
observation). These findings suggest that Tregs are able to convert into
Th1 cells in vitro under certain conditions. While Tregs possess great
plasticity to convert into Th1 and Th17 cells, no evidence has been
presented to show that nTregs can be converted into Th2 cells under
culture conditions. When CD4 T cells were stimulated in the pre-
sence of IL-4 and TGF-b, TGF-b-induced Foxp3 expression was
decreased.105 However, activated T cells did not become IL-4-
producing T cells. Instead, they produced IL-9.106,107 Therefore,
whether Tregs are able to become IL-4-producing cells in vitro remains
unknown.
Plasticity of Tregs in vivo
The aforementioned studies’ efforts were devoted to investigating
cytokine-driven conversion of Tregs. Most of these studies focused
on converting TGF-b-induced iTregs into other types of Th cells under
culture conditions. One of the important questions is whether Tregs
can be converted into other types of Th cells under physiological
conditions. In addition, if such conversions indeed occur in vivo, what
might be the biological significance of such a conversion?
Accumulating evidence has been presented to show that Tregs can
convert into effector T cells in vivo. When an EGFP expression cassette
was knocked into the first exon of the endogenous foxp3 gene, cells that
lacked functional Foxp3 protein but had active Foxp3 promoter activ-
ities were thus marked with green fluorescence protein (GFP). In such
a mouse model, loss of functional Foxp3 resulted in a Scurfy-like
phenotype in the mice. However, in these mice, GFP-expressing cells
were readily detected and were at an elevated percentage compared to
that in the healthy mice. These GFP-expressing cells bore Treg signa-
tures at reduced levels. Although these cells could not suppress the
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Thus, these cells were Treg lineage but with abrogated immunosup-
pressive function. These Tregs were shown to become effector T cells
in vivo by producing IFN-c, IL-4 and IL-17. Therefore, with the loss of
Foxp3 expression, Tregs could be generated but functionally dysregu-
lated by losing suppressive activity and gaining Th1, Th2 and Th17
effector function.108 Without artificially ablating Foxp3 function,
Tregs were also shown to downregulate Foxp3 expression and convert
into effector T cells in vivo. In one study, Zhou et al. generated a
bacterial artificial chromosome transgenic mouse model where Cre
and EGFP were expressed in Foxp3-expressing Tregs 109. By crossing
such a mouse with a yellow fluorescent protein (YFP) Cre-reporter
mouse strain, they tracked all the T cells that were currently expressing
and had previously expressed Foxp3. They found that, in vivo, a small
percentage of CD4 T cells expressed YFP but not GFP, indicating that
these T cells used to express Foxp3 but had shut down the Foxp3
expression at the time of assay. Therefore, downregulation of Foxp3
expression in Tregs normally occurs in vivo. They referred to these YFP
positive and GFP negative cells as exFoxp3 Tregs. In addition, they
found that exFoxp3 Tregs expressed IFN-c and IL-17, suggesting their
conversion into Th1 and Th17 cells. Moreover, exFoxp3 Tregs are able
to promote inflammation and to contribute to the onset of type 1
diabetes upon transfer. Therefore, Treg to Th conversion could be
important for directing inflammatory responses. Following transfer
into the recipients, exFoxp3 Tregs were not able to regain Foxp3
expression, suggesting that conversion of Treg into Th cells is an
irreversible process.109 Th1 conversion of Tregs was also reported
during lethal parasitic infection.110 When mice were infected with
a lethal dose of Toxoplasma gondii, Foxp3-expressing Tregs became
IFN-c-producing Th1 cells. Interestingly, a decrease of Foxp3 expres-
sion was not associated with Treg to Th1 conversion in this study.
Evidence for Treg to Tfh conversion in vivo is also available.
Upon transfer into CD32/2 mice where T cells were absent, Foxp3-
expressing Tregs downregulate Foxp3 expression in Peyer’s patches.
The transferred Foxp3-non-expressing Tregs but not Foxp3-
expressing Tregs clustered around germinal centers, expressing
CXCR5, IL21 and Bcl6, a phenotype resembling Tfh.111
In the studies mentioned above, Treg to Th conversion invariantly
concurred with the loss of Foxp3 expression, suggesting that conver-
sion and Foxp3 expression might be mutually exclusive, and question-
ing the intrinsic ability of Tregs to become other types of Th cells in
vivo. By knocking a luciferase and EGFP-expressing cassette into the
39-untranslated region of the endogenous Foxp3 gene locus, we ser-
endipitously generated a mouse model whose Tregs expressed Foxp3
but with reduced levels.112 Reduction of Foxp3 expression resulted in a
systemic autoimmune syndrome similar to what has been observed in
Scurfy mice. Further analysis revealed that Foxp3-expressing T cells
were generated in these mice, but without suppressive activities,
although they remained anergic to T-cell receptor stimulation.
Interestingly, reduction of Foxp3 led to a preferential conversion of
Tregs into IL-4-producing Th2 cells.112 Th2 conversion of Tregs might
be essential for directing Th2 responses, as reduced Foxp3 expression
in Tregs has been associated with Th2-type immune disorders in dif-
ferent mouse models. Thus, in vivo, Foxp3 expression and Treg to Th
conversion are not mutually exclusive. Additionally, the expression of
Foxp3 seems to limit the potential of Tregs to be converted into all
types of Th cells. Whether Tregs with reduced Foxp3 expression are
able to convert into other types of Th cells remains to be addressed.
More importantly, it appears that the expression levels of Foxp3 con-
trol Treg function: high levels of Foxp3 expression endow T cells with
suppressive activity; reduced levels lead to Th2 conversion and loss of
Foxp3 licenses Tregs to Th1, Th2, Th17 and Tfh conversion. Thus,
Foxp3 serves as a rheostat controlling the diverse function of Tregs
in vivo. The mechanisms underlying such phenomena are important
questions deserving to be addressed in the future. In addition, as
Foxp3 downregulation is a critical trigger for Treg to Th conversion
in vivo, what triggers Foxp3 downregulation, or alternatively, what
maintains high levels of Foxp3 expression, are questions that need
to be addressed. Furthermore, the biological functions of Treg con-
version during normal and aberrant immune responses still wait to be
revealed.
While the signal transduction network controlling Treg to Th con-
version waits to be unveiled, studies on epigenetic control of Treg and
Th differentiation have provided important mechanistic insights. T-
lineage specification is accompanied by epigenetic modifications of
key cytokine and transcription factor gene loci. Such epigenetic change
provides a basis for the heritability of gene expression patterns
acquired by differentiating T cells.113,114 Histone methylation or acet-
ylation, DNA methylation and higher order chromatin structure each
contribute to regulation of the accessibility of cis elements that bind
lineage-specifying transcription factors and ultimately the expression
of lineage-specific genes. The growing recognition of instability in the
functional T-cell repertoire, as demonstrated in particular by plasticity
of Treg programs, implies greater malleability in T-cell epigenetic
modifications than previously thought, and suggests that conversion
of Tregs is likely reflected in the reversal of epigenetic modifications
induced during initial differentiation of these cells.
A global genome analysis of permissive and repressive histone
methylation marks of naive, Th1, Th2, Th17 cells, nTregs and iTregs
was recently reported, providing a mechanistic basis for aspects of
Treg conversion.104 Trimethylations of histone H3 were identified at
the proximal promoters of key T-lineage transcription factors or cyto-
kine genes. H3K4me3 and H3K27me3 were used to mark the genes
that are expressed or repressed, respectively. The promoters for the
genes highly expressed in certain Th lineages correlated with permiss-
ive H3K4me3 configuration. However, the promoters for the genes
not expressed were not necessarily associated with high amounts of
repressive H3K27me3 configuration. While only a small number of
lineage-specific H3-methylation islands were found for Th cells, a
large number of the unique H3K4me3 and H3K27me3 islands were
found in nTregs, underlying their greater potential for diverse func-
tions. Indeed, although the promoters for IFN-c, IL-4 and IL-17A
were not marked with H3K4me3 for active expression, they were
not marked with H3K27me3 for active suppression either. In addition,
transcription factors T-bet, GATA3 and ROR-ct that master Th1, Th2
and Th17 differentiation, respectively, were not marked with the sup-
pressive configuration in Tregs. Thus, at the epigenetic level, Tregs did
not shut down the genetic program for other Th cells and remained
permissive for their differentiation.104
FINAL REMARKS
Being initially identified as suppressor T cells, Foxp3-expressing cells
are critical in maintaining self-tolerance and immune homeostasis.
With collective efforts over many years, we have achieved tremendous
progress in understanding the immunological function of Tregs as
well as how this type of T cells is regulated during normal and patho-
logical immune responses. Recently, evidence has suggested that
immunosuppression might not be the only function of Foxp3-expres-
sing cells. They may convert into proinflammatory cells to promote
immune responses. Such findings have important biological implica-
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aberrant function of Tregs and Treg to Th conversion could be critical
in instigating and directing unwanted immunopathologies. Therefore,
understanding how Treg to Th conversion occurs should enhance our
understanding of the etiology of autoimmunity and inflammatory
diseases. By generating reporter mice for Tregs and different subtypes
of Th cells, we have started to unravel the diverse function of Tregs
in vitro and in vivo. Future studies to investigate the molecular
mechanisms of Treg to Th conversion and to address what impact
such converted Tregs might have on various immune disorders are
warranted.
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